SequelSEC

Coya Therapeutics, Inc. COYA

Pharmaceutical Preparations · CIK 0001835022 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$7.95M
Fiscal year ended 2025-12-31
Operating income
-$22.56M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Coya Therapeutics, Inc. (COYA) reported revenue of $7.95M and net income of -$21.23M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Coya Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Coya Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$7.95M$3.55M$6.00M$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$22.56M-$17.25M-$7.90M-$9.81M
Net income-$21.23M-$14.88M-$7.99M-$12.24M
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 16.73Mshares 15.24Mshares 10.16Mshares 2.59M
Pretax income-$21.22M-$15.60M-$7.26M-$12.24M
Income tax expense$3.09K-$720.29K$723.85K$0
Diluted EPS$-1.27$-0.98$-0.79$-4.73
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$11.45M$8.89M$7.83M$4.85M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Coya Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$46.82M$38.34M$32.63M$5.93M
Total assets$49.95M$44.35M$41.26M$8.40M
Current assets$49.94M$44.31M$41.20M$7.18M
Total liabilities$6.92M$4.77M$5.63M$16.79M
Current liabilities$5.87M$3.82M$5.05M$3.82M
Total equity incl. NCI$43.03M$39.58M$35.64M-$8.39M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.06M$1.59M$1.16M$1.82M

Cash flow

Coya Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$10.74M-$10.29M-$11.19M-$7.24M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$1.16M-$25.00K-$543.19K-$525.00K
Financing cash flow$20.39M$16.03M$38.43M$9.36M
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$4.29M$2.66M$872.25K$207.35K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Coya Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-283.9%-485.4%-131.7%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenue54.0%74.9%14.5%Unavailable
Current ratio8.50x11.59x8.15x1.88x
Revenue YoY growth123.6%-40.8%UnavailableUnavailable
Net margin-267.1%-418.7%-133.1%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open COYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.